India's Cipla to buy Hetero Drugs' US business for about $550 mln

September 4, 2015 3:30 AM

25 0

MUMBAI, Sept 4 Indian generic drugmaker Cipla Ltd is set to buy the U.S. business of privately held rival Hetero Drugs for about $550 million, the Economic Times newspaper reported on Friday, citing people close to the transaction.

The newspaper said Cipla would buy U.S.-based Camber Pharmaceuticals and InvaGen Pharmaceuticals. (

Also read: Impax broke U.S. antitrust law by delaying generic drug, jury told

Read more

To category page